Background: One strategy for managing recurrent uncomplicated urinary tract infections (UTIs) is prevention. This study tested OM-89S, a lyophilized lysate of 18 Escherichia coli strains manufactured using a modified lytic process. Methods: This was a randomized, double-blind trial in 451 female subjects with recurrent uncomplicated UTIs. Period 1 of the study tested 6 mg of OM-89S versus placebo (3 months), plus a 3-month observation. Period 2 of the study was a 3-month treatment period (each monthly cycle consisted of 6 mg of OM-89S daily for 10 days and placebo for 20 days, vs. 50 mg nitrofurantoin daily for 30 days), plus a 3-month observation. Results: There was no difference in the mean rate of UTI episodes between the OM-89S (0.66 ± 0.93) and placebo groups (0.63 ± 0.86; p = 0.95) in period 1. Similar findings were obtained for period 2. OM-89S was well-tolerated. Conclusions: Our results did not demonstrate a preventive effect of OM-89S compared to placebo. This may be due to the low number of UTIs that occurred during the study, the high number of protocol violations, and/or the modified manufacturing process used for OM-89S.

Keywords:
Urinary tract infection, Escherichia coli lysate, OM-89S, Nitrofurantoin, Immune response
1.
Foxman B, Brown P: Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 2003;17:227-241.
2.
Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P, et al: Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000;151:1194-1205.
3.
Alidjanov JF, Abdufattaev UA, Makhsudov SA, Pilatz A, Akilov FA, Naber KG, et al: New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol Int 2014;92:230-236.
4.
Rodrigues P, Hering F, Campagnari JC: Involuntary detrusor contraction is a frequent finding in patients with recurrent urinary tract infections. Urol Int 2014;93:67-73.
5.
Brumbaugh AR, Mobley HL: Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines 2012;11:663-676.
6.
Zhang X, Niu S, Zhang L: Antimicrobial susceptibilities and clinical characterization of pseudomonas aeruginosa isolates from urinary tract infections. Urol Int 2014;93:464-469.
7.
Ronald AR, Pattullo AL: The natural history of urinary infection in adults. Med Clin North Am 1991;75:299-312.
8.
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-e120.
9.
Albert X, Huertas I, Pereiro, II, Sanfelix J, Gosalbes V, Perrota C: Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;3:CD001209.
10.
Grabe M, Bjerklund-Johansen TE, Botto H, Cek M, Naber KG, Pickard RS, Tenke P, Wagenlehner F, Wullt B: Guidelines on Urological Infections. Arnhem, European Association of Urology Guidelines, 2014, pp 1-100.
11.
Dethlefsen L, Huse S, Sogin ML, Relman DA: The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008;6:e280.
12.
Hooton TM, Roberts PL, Stapleton AE: Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 2012;307:583-589.
13.
MacDonald TM, Beardon PH, McGilchrist MM, Duncan ID, McKendrick AD, McDevitt DG: The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med 1993;86:419-424.
14.
Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC: Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol 2012;69:265-268.
15.
Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al: Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014;14:742-750.
16.
Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC, et al: A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol 2005;47:542-548, discussion 548.
17.
Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS: Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents 2002;19:451-456.
18.
Magasi P, Panovics J, Illes A, Nagy M: Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol 1994;26:137-140.
19.
Naber KG, Cho YH, Matsumoto T, Schaeffer AJ: Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents 2009;33:111-119.
20.
Tammen H: Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol 1990;65:6-9.
21.
Berry RE, Klumpp DJ, Schaeffer AJ: Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli. Infect Immun 2009;77:2762-2772.
22.
Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ: Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007;4:e329.
23.
Dason S, Dason JT, Kapoor A: Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J 2011;5:316-322.
24.
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al: The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009;34:407-413.
25.
Kahan NR, Chinitz DP, Kahan E: Longer than recommended empiric antibiotic treatment of urinary tract infection in women: an avoidable waste of money. J Clin Pharm Ther 2004;29:59-63.
26.
Kahan NR, Chinitz DP, Waitman DA, Kahan E: Empiric treatment of uncomplicated UTI in women: wasting money when more is not better. J Clin Pharm Ther 2004;29:437-441.
27.
Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D'Elia C, et al: The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis 2012;55:771-777.
28.
Barbosa-Cesnik C, Brown MB, Buxton M, Zhang L, DeBusscher J, Foxman B: Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis 2011;52:23-30.
29.
Wybran J, Libin M, Schandene L: Activation of natural killer cells and cytokine production in man by bacterial extracts. Immunopharmacol Immunotoxicol 1989;11:17-32.
30.
Wybran J, Libin M, Schandene L: Enhancement of cytokine production and natural killer activity by an Escherichia coli extract. Onkologie 1989;12(suppl 3):22-25.
31.
Hockertz S: Immunomodulating effect of lysed immunoactive fractions of selected Escherichia coli strains on the macrophage system. An in vitro study (in German). Arzneimittelforschung 1990;40:1068-1072.
32.
Baier W, Sedelmeier EA, Bessler WG: Studies on the immunogenicity of an Escherichia coli extract after oral application in mice. Arzneimittelforschung 1997;47:980-985.
33.
Czerwionka-Szaflarska M, Pawlowska M: Influence of Uro-Vaxom on sIgA level in urine in children with recurrent urinary tract infections. Arch Immunol Ther Exp (Warsz) 1996;44:195-197.
34.
Frey C, Obolensky W, Wyss H: Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier. Urol Int 1986;41:444-446.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.